J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
Potential For Post-Tagrisso Therapy Niche
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
You may also be interested in...
Sponsors of six new products, including a first-in-class treatment for unresectable locally advanced or metastatic triple-negative breast cancer, will find out this week if their products are on course to be approved for use in the EU. Also, two sponsors might be asked to address last-minute questions about their drugs.
The antibody discovery and development biotech Genmab is preparing to commercialize its own products in the second half of 2021, as revenues continue to grow from partners and licensees.
Competition may be on the horizon but Tagrisso's position as standard of care for EGFR-mutated NSCLC looks solid, not least after a thumbs-up in the EU for the adjuvant treatment of adults with early-stage disease.